NEW YORK, March 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that preclinical feasibility data supporting an Actinium-225 ...

NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into ...

BELOIT, Wis. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for ...

BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications ...

image: Cerium/lanthanum-134-based radiopharmaceuticals have promise for prostate cancer imaging and therapy. Right, tumors show high tumor uptake of cerium-134. Left, a comparison of cerium-134 and ...

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Incoming Orders/Contract Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope ...

NEW YORK, Oct. 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today ...

- ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi ® (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination - ...

NorthStar to provide non-carrier added actinium-225 (n.c.a Ac-225) to Cellectar for use in its expanded portfolio of clinical programs This includes CLR 121225 an actinium-labeled phospholipid ether ...

Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the ...

Actinium-targeted alpha radiotherapy is a promising approach for treating metastatic cancers, including prostate cancer. This approach requires doctors to obtain images of the radiotherapy agent as it ...

CAMBRIDGE, Mass. and JENKINTOWN, Pa., May 25, 2022 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical stage radiopharmaceutical company, and IONETIX Corporation, a leading cyclotron technology, ...